Long non-coding RNA MALAT1 enhances the protective effect of dexmedetomidine on acute lung injury by sponging miR-135a-5p to downregulate the ratio of X-box binding proteins XBP-1S/XBP-1U

Pengyi Li, Lianbing Gu, Qingming Bian, Dian Jiao, Zeping Xu, and Lijun Wang

Department of Anesthesiology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

ABSTRACT
Acute lung injury (ALI) is the common and clinically severe complication. Dexmedetomidine (DEX) can protect against lipopolysaccharide (LPS)-induced ALI through anti-apoptosis, anti-inflammatory and immune regulatory actions. It is well documented that major causes of LPS-induced ALI are endoplasmic reticulum stress (ERS) and abnormally elevated CHOP. Moreover, XBP-1 can enhance CHOP expression. XBP-1S can aggravate ERS and XBP-1 U can repress ERS. By querying Starbase, miR-135a-5p interacts with XBP-1 and IncRNA MALAT1 sponges miR-135a-5p. It has been reported that MALAT1 interference markedly promoted the apoptosis of pulmonary microvascular endothelial cells in ALI rats by activating TLR4/NF-κB pathway, miR-135a-5p inhibitor remarkably alleviated LPS-induced A549 cell injury through suppressing cell apoptosis. In the present work, LPS was dripped into the nasal cavity of SD rats to establish the rat model of ALI and LPS was also applied to stimulate BEAS-2B cells to imitate ALI in vitro. Then, the pathology, lung function indexes, levels of inflammatory factors, apoptosis of lung tissues in SD rats and apoptotic level of BEAS-2B cells were measured, so as to confirm whether upregulation of IncRNA MALAT1 was able to suppress ERS, thus enhancing the protective effect of DEX against ALI. Herein, overexpression of IncRNA MALAT1 strengthened the remission effects of DEX on LPS-triggered ALI, severe pulmonary edema, inflammatory response and cell apoptosis of lung tissues in SD rats and reinforced the anti-apoptosis effect of DEX on LPS-stimulated BEAS-2B cells. Mechanically, IncRNA MALAT1 enhanced the protective effect of DEX against ALI by downregulating the ratio of XBP-1S/XBP-1U to repress ERS.

Introduction
Acute lung injury (ALI) and its severe form acute respiratory distress syndrome (ARDS) are common and clinically severe complications [1]. The patients are manifested by hypoxemia and decrease in lung compliance [2]. Although in the past few years, the development of intensive care medicine contributes to the significant drop in the incidence and mortality of ALI and ARDS [3]. There is still a lack of clinically effective therapies [4]. Therefore, there is an urgent need to develop appropriate therapeutic drugs or targets to better carry out the precision treatment.

The bacterial endotoxin, lipopolysaccharide (LPS), is a highly proto-inflammatory factor that can trigger systemic inflammation. In lung tissues, LPS is the stimulating factor that induces inflammatory response, resulting in damage and ultimately leading to lung injury. LPS-induced ALI is a widely accepted animal model [5]. Dexmedetomidine (DEX) is an adrenergic receptor agonist with good sedative effect and is widely applied in the process of clinical therapeutics [6]. It has been reported that DEX treatment can protect against LPS-induced ALI through anti-apoptosis, anti-inflammatory and immune regulatory actions [7–9]. However, the specific mechanism of DEX in ALI needs to be further explored.

Non-coding RNA is a type of RNA that cannot encode proteins [10]. At present, accompanied by more extensive researches on microRNAs (miRNAs) and long noncoding RNAs (lncRNAs),
increasing studies about the correlations among lncRNAs, miRNAs and ALI pathogenesis are carried out [11,12]. It has been proved that lncRNA MALAT1 was significantly downregulated in ALI rats, and MALAT1 interference markedly promoted the apoptosis of pulmonary microvascular endothelial cells in ALI rats by activating TLR4/NF-κB pathway [13]. Literature also verifies that lncRNA MALAT1 could act as a ceRNA to modulate miR-135a-5p expression [14]. In addition, miR-135a-5p inhibitor remarkably alleviated LPS-induced A549 cell injury through suppressing cell apoptosis [15].

Endoplasmic reticulum can avoid the accumulation of misfolded and unfolded proteins by activating a series of signaling pathways, and then maintain eukaryotic cell homeostasis, which is called endoplasmic reticulum stress (ERS) [16]. It is well documented that major causes of LPS-induced ALI are ERS and abnormally elevated expression of ERS-related C/EBP-homologous protein (CHOP) [17,18]. During the onset and development of ERS, CHOP expression is closely associated with the activation of protein kinase RNA-like ER kinase (PERK)/activating transcription factor 4 (ATF4) and ATF6 pathways [19–21]. In addition, some studies also reveal that another ERS-related X-box binding protein 1 (XBP-1) can enhance CHOP expression [22,23]. The activity and function of XBP-1 are mainly determined by its spliceosome. The changing of nucleotide sequence of XBP-1 mRNA leads to the alternation of amino acid sequence of XBP-1 protein (XBP-1S). XBP-1S can aggravate the unfolded protein response (UPR) and ERS. Additionally, XBP-1 U, which is formed by normal XBP-1 mRNA, can repress UPR and ERS [24,25]. By querying Starbase (http://starbase.sysu.edu.cn/), it is confirmed that miR-135a-5p interacts with normal mRNA of XBP-1, therefore targeting and degrading it. Furthermore, application of DEX could also ameliorate oxidative stress and cell apoptosis in kidney tissues by suppressing ERS [26].

Here, LPS-induced ALI in SD rat model was established and BEAS-2B cells were stimulated by LPS to imitate ALI in vitro. The pathology, lung function indexes, levels of inflammatory factors and cell apoptosis of lung tissues in SD rats and apoptosis of BEAS-2B cells were measured, so as to confirm whether upregulation of lncRNA MALAT1 was able to suppress ERS, thus enhancing the protective effect of DEX against ALI.

Material and methods

Establishment of rat model of acute lung injury

SD rats were obtained from the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences (Shanghai, China). All experiments were approved and performed according to the guidelines of the Ethics Committee of Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University. LPS (7.5 mg/kg) was dripped into the nasal cavity of SD rats to establish the rat model of acute lung injury. 1 h before LPS stimulation, DEX (5 mg/kg; Jiangsu Hengrui Pharmaceutical Co., Ltd., Lianyungang, China) was intraperitoneally injected for lung protection. MALAT1 overexpression lentivirus (Over-MALAT1) and corresponding negative control (Over-NC) were designed by the Genechem (Shanghai, China). SD rats were injected with overexpression lentivirus or control lentivirus 3 d before LPS stimulation. In the current work, the in vivo experimental groups were divided into five groups as follows: (I) Control; (II) Non-treated acute lung injury (ALI) rats (Model); (III) ALI rats receiving pre-treatment with DEX; (IV) ALI rats receiving tail vein injection with Over-NC and pre-treatment with DEX; (V) ALI rats receiving tail vein injection with Over-MALAT1 and pre-treatment with DEX. After sacrificing rats, lung tissues were collected for subsequent analysis.

Determination of lung water content

Lung water content was determined to evaluate the pulmonary edema. SD rats were sacrificed and lungs were collected. Wet weight and dry weight of lungs were measured before and after drying at 80°C for 48 h. Values of lung water content is calculated according to the following formula: lung water content (%) = (wet weight-dry weight)/wet weight × 100%.
**Total protein content and cell counts in bronchoalveolar lavage fluid (BALF)**

SD rats were sacrificed and BALF was obtained by injection and retraction of 2 ml PBS thrice. Then, the collected solution was centrifuged at 1,200 × g for 10 min at 4°C. The supernatants were used for determination of total protein content in BALF with bicinchoninic acid (BCA) commercial kits (Beyotime, Shanghai, China). All operations during experiments followed the instructions.

Cell pellet was resuspended in PBS, and cell counts were determined using a hemocytometer following Wright-Giemsa staining for 10 min.

**Enzyme-linked immunosorbent assay (ELISA)**

ELISA was performed to detect the levels of inflammatory factors in lung tissues. TNF-α Rat ELISA kit (Abcam, ab100785, MA, USA), IL-1β Rat ELISA kit (Abcam, ab100768, MA, USA), IL-6 Rat ELISA kit (Abcam, ab100772, MA, USA) and MPO Rat ELISA kit (Nanjing Jiancheng Bioengineering Institute, A044-1-1, Nanjing, China) were used for the experiments. All operations of ELISA assays followed the instructions.

**TUNEL staining**

Lung tissues of SD rats were sectioned and treated with proteinase K working solution. After that, these slices were washed with PBS thrice. Next, terminal deoxynucleotidyl transferase (TdT) was incubated with these sections for 15 min. Thereafter, these sections were incubated with TUNEL reaction mixture (Roche, Basel, Switzerland) for 1 h. 4′, 6-diamidino-2-phenylindole (DAPI) was applied for the nuclear staining and incubated in the dark. The fluorescent microscope (Olympus, Tokyo, Japan) was used for acquiring images.

**Lung histopathological analysis**

Lung tissues of SD rats were placed in 10% formalin overnight, dehydrated and embedded with paraffin. Then, lung tissues were cut into 5 μm sections. Next, these slices were stained with the hematoxylin and eosin (H&E). In addition, the lung sections were stained with periodic acid-Schiff (PAS). All these sections were observed with the microscope (Olympus, Tokyo, Japan).

**Luciferase reporter assay**

Interactions between lncRNA MALAT1 and miR-135a-5p or miR-135a-5p and XBP-1 were assessed via luciferase reporter assay. The amplified lncRNA MALAT1 or XBP-1 3′-UTR sequence and lncRNA MALAT1 MUT or XBP-1 MUT 3′-UTR sequence were inserted into the pGL3 vector (Promega, WI, USA) to construct the luciferase reporter lncRNA MALAT1-WT or XBP-1-WT and lncRNA MALAT1-MUT or XBP-1-MUT. Then, cells were co-transfected with luciferase reporter and miR-135a-5p mimic or mimic NC. The samples were harvested after 48 h and the luciferase activity was evaluated by commercial kits (Promega, WI, USA). Renilla luciferase values were used to normalize Firefly luciferase values. All the operations followed the instructions.

**Cell culture and treatment**

BEAS-2B cells were obtained from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (HyClone, UT, USA) supplemented with 10% fetal bovine serum (Gibco, NY, USA) at 37°C in a humidified atmosphere with 5% CO₂ and 95% air. BEAS-2B cells were incubated with 4 μg/ml LPS and/or 10 μM DEX for 24 h.

**Cell transfection**

LncRNA MALAT1 overexpression lentivirus and corresponding negative control were obtained from Genechem (Shanghai, China). LncRNA MALAT1 was overexpressed in BEAS-2B cells by transfecting with the lentivirus. Polybrene (Genechem, Shanghai, China) was applied to enhance the efficiency of transfection according to the manufacturer’s instruction. Briefly, cells (2 × 10⁵/well) were seeded into 24-well plates. 2 μg vectors were mixed with 10 μg/ml polybrene (Santa Cruz Biotechnology, CA, USA) in complete medium. Then, the mixture was added into the plate and transfections were performed at 37°C for 6 h. Subsequently, the medium was replaced with
fresh medium and positive cells were selected with 10 μM puromycin (Santa Cruz Biotechnology, CA, USA).

**Cell counting kit-8 (CCK-8) assay**

CCK-8 assay was applied for detection of the viability of BEAS-2B cells. Cells were plated into 96 well plates (2 x 10^3 cells/hole). After 24 h incubation, CCK-8 reagent (Dojindo, Kumamoto, Japan) was added into 96 well plates and cultured for another 2 h at 37°C in the incubator. After that, absorbance of each well at 450 nm was detected using a microplate reader (Bio-Rad, CA, USA).

**Western blotting analysis**

Total proteins were extracted using RIPA buffer (Beyotime, Shanghai, China) and the concentration of protein samples was determined via BCA (Beyotime, Shanghai, China) methods. Thereafter, protein samples were separated by 10% SDS-PAGE gel (Beyotime, Shanghai, China) and transferred to PVDF membranes (Millipore, MA, USA). PVDF membranes were blocked in 5% skim milk powder for 1 h and then incubated with primary antibodies at 4 °C overnight. The primary antibodies used in this research were IRE-1 (Abcam, ab37073, 1:2000), CHOP (CST, #5554, 1:1000), XBP-1 U (Abcam, ab37152, 1:2000), XBP-1S (CST, #40,435, 1:1000), Caspase-12 (Abcam, ab62484, 1:1000), Bax (Abcam, ab32503,1:5000), Bcl-2 (Abcam, ab32124, 1:1000), Caspase-3 (Abcam, ab13847, 1:500), Cleaved caspase-3 (Abcam, ab2302, 1:500) and GAPDH (Abcam, ab9484, 1:1000). On the second day, PVDF membranes were washed with PBST for three times and incubated with second antibodies for 2 h at room temperature. At last, protein signals were developed with enhanced chemiluminescence reagents (Pierce, IL, USA) and analyzed with Image J software.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)**

Total RNA was extracted using Trizol (Thermo Fisher Scientific, MA, USA) methods. Next, mRNA was converted into cDNA with the reverse transcription kit (Roche, Basel, Switzerland). Then, cDNA was amplified with ABI 7500 system (Thermo Fisher Scientific, MA, USA). SYBE Green was used for the detection of fluorescence signal. The sequences of primers were as follows: MALAT1 forward: 5’-GACGAGGTGGAGATGAGC-3’ and reverse: 5’- ATTCGGGCTCTGATGCTCT-3’; miR-135a-5p forward: 5’- GGCCTCGCTTTCTC ATTGG-3’ and reverse: 5’- GCCACGGGTC CAATCCCTAT-3’; GAPDH forward: 5’-AACGGAAGCTGTCATCAAAGGAA-3’ and reverse: 5’- GCATCGACAGGGGGC AGAG-3’; U6 forward: 5’-CTCGCTTCGGCAGCACAA-3’ and reverse: 5’-AACGITTACCAGAATTGCGT-3’. 2^−ΔΔCt was applied for calculation of the relative expressions of target genes [27].

**Statistical analysis**

Experimental data in this research was analyzed using Graphpad Prism 7.0 (GraphPad Software Inc., CA, USA) and expressed as mean ± standard deviation (SD). All the experiments were repeated in triplicate. One-way analysis of variance followed by Tukey’s post hoc test was performed to evaluate the differences among diverse groups. The difference was considered as statistically significant when P value was less than 0.05. *p < 0.05, **p < 0.01, ***p < 0.001.

**Results**

**Overexpression of lncRNA MALAT1 enhanced the protective effects of DEX on LPS-induced ALI**

In order to identify the regulatory function of lncRNA MALAT1 in ALI, SD rats received tail vein injection with MALAT1 overexpression lentivirus or control lentivirus. The efficacy of lentivirus was verified by performing RT-qPCR (Figure 1(a)). HE staining and PAS staining for lung histopathological analysis were performed to determine the effects of lncRNA MALAT1 on LPS-induced ALI. The alveolar structures of control rats are complete, and there is no obvious inflammatory cell infiltration in the lung interstitium and alveolar cavity. In ALI rats, the structure of lung tissue was disordered and mainly manifested as obvious thickening of alveolar septum, infiltration of a large number of inflammatory cells
and red blood cells in the lung interstitium and alveolar cavity and partial rupture of alveolar septum. Then, it was observed that DEX therapy relieved the symptoms of lung tissues in ALI rats. Moreover, overexpression of lncRNA MALAT1 further enhanced the therapeutic effects of DEX on ALI (Figure 1(b,c)). Lung water content was determined to evaluate the pulmonary edema. DEX treatment alleviated severe pulmonary edema in ALI rats and overexpression of lncRNA MALAT1 enhanced the remission effect of DEX (Figure 2(a)). In addition, LPS stimulation induced higher levels of total protein content and cell counts in BALF. DEX therapy relieved these symptoms during the development of ALI and upregulation of lncRNA MALAT1 also strengthened the protective role of DEX in ALI (Figure 2(b,c)).

**Overexpression of lncRNA MALAT1 enhanced the relieving effect of DEX on LPS-triggered inflammatory response of lung tissues**

Inflammatory response is a complex biological reaction during multiple tissue damage. Results from ELISA assays demonstrated that DEX

![Figure 1](image1)

![Figure 2](image2)
therapy reduced the high levels of TNF-α, IL-1β, IL-6 and MPO in lung tissues of ALI rats. Moreover, the relieving effect of DEX on LPS-triggered inflammatory response of lung tissues was further strengthened after elevation of lncRNA MALAT1 (Figure 3).

**Overexpression of lncRNA MALAT1 enhanced the inhibitory effect of DEX on cell apoptosis in ALI**

Furthermore, TUNEL staining was performed to assess cell apoptosis in lung tissues. In ALI rats, LPS stimulation triggered cell apoptosis in lung tissues, which was hindered after DEX therapy. In addition, overexpression of lncRNA MALAT1 further strengthened the anti-apoptosis effect of DEX (Figure 4(a,b)). After that, levels of apoptosis-related proteins in lung tissues were detected using western blotting assay. It was observed that expression level of Bcl-2 was reduced and expression levels of Bax and Cleaved caspase-3 were elevated after LPS stimulation. DEX therapy recovered Bcl-2 expression and suppressed Bax and Cleaved caspase-3 expression. Additionally, upregulation of lncRNA MALAT1 further strengthened the regulatory effects of DEX on the expression levels of apoptosis-related proteins in lung tissues, suggesting that lncRNA MALAT1 could enhance the anti-apoptosis effect of DEX in ALI (Figure 4(c)).

**lncRNA MALAT1 strengthened the protective effect of DEX on ALI by sponging miR-135a-5p to suppress ERS**

In lung tissues of ALI rats, obviously decreased lncRNA MALAT1 expression and increased miR-135a-5p expression were observed. DEX treatment slightly rescued the level of lncRNA MALAT1 and visibly suppressed miR-135a-5p expression. Overexpression of lncRNA MALAT1 enhanced the regulatory effects of DEX on the expressions of lncRNA MALAT1 and miR-135a-5p (Figure 5(a, b)). For subsequent experiments, miR-135a-5p was overexpressed in BEAS-2B cells by transfecting miR-135a-5p mimic (Figure 5(c)). By retrieving Starbase, lncRNA MALAT1 can interact with miR-135a-5p, hinting its potential to sponge miR-135a-5p (Figure 5(d)). Luciferase reporter assay revealed that upregulation of miR-135a-5p distinctly decreased the luciferase activity of MALAT1-WT while had no inhibitory effect on the luciferase activity of MALAT1-MUT (Figure 5(e)). In addition, interaction between miR-135a-5p and XBP-1 was verified by querying Starbase and performing luciferase reporter assay (Figure 5(f,g)). Upregulation of miR-135a-5p significantly decreased the luciferase activity of XBP-1-WT while had no inhibitory effect on that of XBP-1-MUT. These findings prompted that lncRNA MALAT1 could sponge miR-135a-5p to manipulate the expression of XBP-1. Then, expressions of ERS-related proteins in lung tissues were assessed via western blotting analysis. Levels of IRE-1, XBP-1S, Caspase-12 and CHOP were elevated and level of XBP-1 U was reduced after LPS stimulation. The increased ratio of XBP-1S/XBP-1 U was observed in lung tissues of ALI rats. Treatment of DEX restricted the expressions of IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U. Additionally, overexpression of lncRNA MALAT1 recovered XBP-1 U expression and further suppressed the expressions of IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U (Figure 6). Hence, we concluded that lncRNA MALAT1 may reinforce the protective

![Figure 3](image-url) **Figure 3.** Overexpression of lncRNA MALAT1 enhanced the relieving effect of DEX on LPS-triggered inflammatory response of lung tissues. Levels of TNF-α, IL-1β, IL-6 and MPO in lung tissues were determined with ELISA assays.
effect of DEX against ALI by sponging miR-135a-5p to suppress ERS.

**Overexpression of lncRNA MALAT1 reinforced the anti-apoptosis effect of DEX on LPS-stimulated BEAS-2B cells**

Furthermore, the biological function of lncRNA MALAT1 was investigated in LPS-stimulated BEAS-2B cells. LPS stimulation suppressed the viability of BEAS-2B cells and application of DEX relieved cell injury caused by LPS. Overexpression of lncRNA MALAT1 further recovered the viability of LPS-stimulated BEAS-2B cells, enhancing the protective effect of DEX (Figure 7(a)). Next, the expressions of apoptosis-related proteins were determined with western blotting assay. LPS stimulation reduced the level of Bcl-2 and elevated the
levels of Bax and Cleaved caspase-3 in BEAS-2B cells, which were partly reversed by DEX therapy. In addition, overexpression of lncRNA MALAT1 further increased Bcl-2 expression and decreased the expressions of Bax and Cleaved caspase-3, strengthening the anti-apoptosis effect of DEX on LPS-stimulated BEAS-2B cells (Figure 7(b,c)).

**LncRNA MALAT1 enhanced the protective effect of DEX on LPS-stimulated BEAS-2B cells by manipulating IRE-1/XBP-1 pathway to suppress ERS**

Meanwhile, expressions of IRE-1, XBP-1S, XBP-1 U, Caspase-12 and CHOP in BEAS-2B cells were determined using western blotting assay. In LPS-stimulated BEAS-2B cells, obviously increased expressions of IRE-1, XBP-1S, Caspase-12, CHOP as well as elevated ratio of XBP-1S/XBP-1 U and decreased expression of XBP-1 U were observed. DEX therapy suppressed IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U and rescued XBP-1 U, thereby repressing ERS. Importantly, overexpression of lncRNA MALAT1 reinforced the regulating effects of DEX on IRE-1/ XBP-1 pathway and then further suppressed ERS to protect against cell injury caused by LPS (Figure 8).

**Discussion**

ALI is a severe lung disease. Although several progress has been achieved in the prevention and treatment, the mortality rate of ALI still remains high [2,4]. At present, there are plenty of literature reports focusing on the protective effect of DEX on LPS-induced ALI [7–9]. Here, in this current work, LPS was dripped into the nasal cavity of
SD rats to establish the rat model of ALI and LPS was also applied to stimulate BEAS-2B cells to imitate ALI in vitro. The structures of lung tissues in ALI rats were disordered and mainly manifested as obvious thickening of alveolar septum, infiltration of a large number of inflammatory cells and red blood cells in the lung interstitium and alveolar cavity and partial rupture of alveolar septum. ALI rats emerged with severe pulmonary edema, higher levels of total protein content and cell counts in BALF and obvious cell apoptosis of lung tissues. DEX therapy relieved these symptoms during the development of ALI. In addition, LPS stimulation suppressed the viability of BEAS-2B cells and application of DEX alleviated cell injury caused by LPS.

There is increasing evidence revealing that LPS-induced lung injury is mainly due to elevated expression of CHOP and occurrence of ERS [17,18]. The occurrence and development of ERS
are associated with expressions of ATF-4, ATF-6 and IRE-1 [21,28]. IRE-1 can increase the ratio of XBP-1S/XBP-1 U, thus enhancing CHOP expression and accelerating the development of ERS [29,30]. Additionally, higher levels of XBP-1S can induce UPR in multiple types of cells, therefore leading to the enhancement of CHOP and occurrence of ERS [31]. Furthermore, CHOP expression is elevated during the development of LPS-induced lung injury [32]. In the present study, increased expressions of IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U were observed in lung tissues of ALI rats and LPS-stimulated BEAS-2B cells. Moreover, literature revealed that DEX could alleviate cerebral ischemia reperfusion injury by suppressing the expressions of ERS-related proteins (GRP78, p-PERK, CHOP and Cleaved caspase-12) [33]. Herein, elevated levels of IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U in lung tissues of ALI rats and LPS-stimulated BEAS-2B cells were reversed following DEX therapy, suggesting that DEX could alleviate LPS-induced ALI in vivo and in vitro by suppressing ERS.

Furthermore, by retrieving Starbase, it was verified that miR-135a-5p could interact with XBP-1 and therefore repress the expression of XBP-1 U. A study has also reported that miR-135a-5p could aggravate LPS-induced ALI by inducing cell apoptosis [14]. Additionally, some studies have reported that miR-135a-5p could markedly induce tissue damage and fibrosis [34,35]. Results of our current study supported that downregulation of miR-135a-5p reduced the level of XBP-1S and elevated the level of XBP-1 U, thereby suppressing ERS.

LncRNAs are RNA molecules consisting of more than 200 nucleotides. Increasing studies have confirmed that LncRNAs are frequently involved in multiple types of physiological processes such as cell differentiation, apoptosis and inflammatory responses [36,37]. Importantly, literature reveals that LncRNA MALAT1 can relieve the symptoms of sepsis-induced acute lung injury via TLR4/NF-κB and p38 MAPK signaling pathways [13]. In this study, we disclosed that overexpression of LncRNA MALAT1 reinforced the remission effects of DEX on severe pulmonary edema, inflammatory responses and cell apoptosis of lung tissues in ALI rats, enhancing the protective
effects of DEX on LPS-induced ALI. Through browsing Starbase, it was verified that lncRNA MALAT1 possessed the potential to sponge miR-135a-5p. Besides, there was a research reporting that lncRNA MALAT1 served as a molecular sponge for miR-135a-5p [14]. Luciferase reporter assay showed that lncRNA MALAT1 could interact with miR-135a-5p and negatively regulate miR-135a-5p expression to restrict the biological effect of miR-135a-5p. Next, it was also discovered that overexpression of lncRNA MALAT1 enhanced the inhibitory effects of DEX on the expressions of IRE-1, XBP-1S, Caspase-12, CHOP as well as the ratio of XBP-1S/XBP-1 U. All results above prompted that lncRNA MALAT1 may strengthen the protective effect of DEX on ALI by sponging miR-135a-5p to suppress ERS. Consistent with the findings in the rat model of ALI, lncRNA MALAT1 was proved to enhance the protective effect of DEX on LPS-stimulated BEAS-2B cells by manipulating IRE-1/XBP-1 pathway to suppress ERS.

**Conclusion**

To sum up, overexpression of lncRNA MALAT1 strengthened the remission effects of DEX on LPS-triggered ALI, severe pulmonary edema,
inflammatory response and cell apoptosis of lung tissues in SD rats. Moreover, overexpression of lncRNA MALAT1 reinforced the anti-apoptosis effect of DEX on LPS-stimulated BEAS-2B cells. Mechanically, lncRNA MALAT1 downregulated the ratio of XBP-1S/XBP-1 U to repress ERS, thereby enhancing the protective effect of DEX against ALI. These findings highlighted the protective property of lncRNA MALAT1 in ALI and may provide new strategies for ALI therapy.

**Availability of data and materials**

Datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This study was supported by the talents program of Jiangsu Cancer Hospital [YC201805].

**Ethics approval**

All experiments were approved and performed according to the guidelines of the Ethics Committee of Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University.

**References**

[1] Bhadade RR, de Souza RA, Harde MJ, et al. Clinical characteristics and outcomes of patients with acute lung injury and ARDS. J Postgrad Med. 2011;57 (4):286–290.

[2] Zhang B, Swamy S, Balijepalli S, et al. Direct pulmonary delivery of solubilized curcumin reduces severity of lethal pneumonia. FASEB J. 2019;33(12):13294–13309.

[3] Kasotakis G, Stanfield B, Haines K, et al. Acute respiratory distress syndrome (ARDS) after trauma: improving incidence, but increasing mortality. J Crit Care. 2021;64:213–218.

[4] Peritore AF, Amico R, Siracusa R, et al. Management of acute lung injury: palmitoylolethanolamide as a new approach. Int J Mol Sci. 2021;22(11):5533.

[5] Zhu J, Chen G. Protective effect of FOXP3-mediated miR-146b-5p/Robo1/NF-κB system on lipopolysaccharide-induced acute lung injury in mice. Ann Transl Med. 2020;8(24):1651.

[6] Wu Z, Xue H, Zhang Y, et al. Dexmedetomidine alleviates neurobehavioral impairments and myelination deficits following lipopolysaccharide exposure in early postnatal rats. Life Sci. 2020;263:118556.

[7] Feng X, Guan W, Zhao Y, et al. Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3β/Nrf2 signaling pathway. J Cell Physiol. 2019;234(10):18994–19009.

[8] Xu Y, Zhang R, Li C, et al. Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway. Fundam Clin Pharmacol. 2015;29(5):462–471.

[9] Song Q, Lin L, Chen L, et al. Co-administration of N-acetylcysteine and dexmedetomidine plays a synergistic effect on protection of LPS-induced acute lung injury via correcting Th1/Th2/Th17 cytokines imbalance. Clin Exp Pharmacol Physiol. 2020;47 (2):294–301.

[10] Jan MI, Ali T, Ishtiaq A, et al. Prospective advances in non-coding RNA investigations. Adv Exp Med Biol. 2020;1229:385–426.

[11] Chen C, He Y, Feng Y, et al. Long non-coding RNA review and implications in acute lung inflammation. Life Sci. 2021;269:119044.

[12] Jiang ZF, Zhang L, Shen J. MicroRNA: potential biomarker and target of therapy in acute lung injury. Hum Exp Toxicol. 2020;39(11):1429–1442.

[13] Li H, Shi H, Ma N, et al. BML-111 alleviates acute lung injury through regulating the expression of lncRNA MALAT1. Arch Biochem Biophys. 2018;649:15–21.

[14] Luo L, Wang Y, Hu P, et al. Long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) promotes hypertension by modulating the Hsa-miR-124-3p/nuclear receptor subfamily 3, Group C, Member 2 (NRC3C2) and Hsa-miR-135a-5p/NRC3C2 Axis. Med Sci Monit. 2020;26:e920478.

[15] Zhao J, Li X, Zou M, et al. miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2. Biochem Biophys Res Comm. 2014;452 (4):951–957.

[16] Pao HP, Liao WI, Tang SE, et al. Suppression of endoplasmic reticulum stress by 4-PBA protects against hyperoxia-induced acute lung injury via up-regulating claudin-4 expression. Front Immunol. 2021;12:674316.

[17] Du Y, Zhu P, Wang X, et al. Pirfenidone alleviates lipopolysaccharide-induced lung injury by accentuating BAP31 regulation of ER stress and mitochondrial injury. J Autoimmun. 2020;112:102464.

[18] Endo M, Oyadomari S, Suga M, et al. The ER stress pathway involving CHOP is activated in the lungs of LPS-treated mice. J Biochem. 2005;138(4):501–507.

[19] Yi S, Chen K, Zhang L, et al. Endoplasmic reticulum stress is involved in stress-induced hypothalamic neuronal injury in rats via the PERK-ATF4-ChOP and IRE1-ASK1-JNK pathways. Front Cell Neurosci. 2019;13:190.
[20] Kang X, Yang W, Feng D, et al. Cartilage-specific autophagy deficiency promotes ER stress and impairs chondrogenesis in PERK-ATF4-CHOP-dependent manner. J Bone Miner Res. 2017;32(10):2128–2141.

[21] Guo Q, Li H, Liu J, et al. Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma. J Asthma. 2017;54(2):125–133.

[22] Chan JY, Luzuriaga J, Maxwell EL, et al. The balance between adaptive and apoptotic unfolded protein responses regulates β-cell death under ER stress conditions through XBP1, CHOP and JNK. Mol Cell Endocrinol. 2015;413:189–201.

[23] Li Y, Jiang W, Niu Q, et al. eIF2α-CHOP-Bcl-2/JNK and IRE1α-XBP1/JNK signaling promote apoptosis and inflammation and support the proliferation of Newcastle disease virus. Cell Death Dis. 2019;10(12):891.

[24] Hu MC, Gong HY, Lin GH, et al. XBP-1, a key regulator of unfolded protein response, activates transcription of IGF1 and Akt phosphorylation in zebrafish embryonic cell line. Biochem Biophys Res Commun. 2007;359(3):778–783.

[25] Waldherr SM, Strovas TJ, Vadset TA, et al. Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nat Commun. 2019;10(1):4443.

[26] Chen Y, Feng X, Hu X, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxid Med Cell Longev. 2018;2018:4035310.

[27] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.

[28] Yan B, Liu S, Li X, et al. Preconditioning with endoplasmic reticulum stress alleviated heart ischemia/reperfusion injury via modulating IRE1/ATF6/RACK1/PERK and PGC-1α in diabetes mellitus. Biomed Pharmacother. 2019;118:109407.

[29] Binder P, Wang S, Radu M, et al. Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response. Circ Res. 2019;124(5):696–711.

[30] Lew QJ, Chu KL, Lee J, et al. PCAF interacts with XBP-1S and mediates XBP-1S-dependent transcription. Nucleic Acids Res. 2011;39(2):429–439.

[31] Lew QJ, Chu KL, Chia YL, et al. GCN5 inhibits XBP-1S-mediated transcription by antagonizing PCAF action. Oncotarget. 2015;6(1):271–287.

[32] He M, Shi W, Yu M, et al. Nicorandil attenuates LPS-induced acute lung injury by pulmonary endothelial cell protection via NF-κB and MAPK pathways. Oxid Med Cell Longev. 2019;2019:4957646.

[33] Liu C, Fu Q, Mu R, et al. Dexmedetomidine alleviates cerebral ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress dependent apoptosis through the PERK-CHOP-Caspase-11 pathway. Brain Res. 2018;1701:246–254.

[34] Yang X, Wang X, Nie F, et al. miR-135 family members mediate podocyte injury through the activation of Wnt/β-catenin signaling. Int J Mol Med. 2015;36(3):669–677.

[35] He F, Peng F, Xia X, et al. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia. 2014;57(8):1726–1736.

[36] Fatica A, Bozzi MI. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.

[37] Guttmann M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339–346.